NASDAQ:IRIXIRIDEX Stock Price, Forecast & News

$1.85

-0.05 (-2.63 %)

(As of 04/9/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.82

Now: $1.85▼

$1.90

50-Day Range

$1.40

MA: $2.18▼

$3.45

52-Week Range

$1.22

Now: $1.85▼

$5.69

Volume16,512 shs

Average Volume61,202 shs

Market Capitalization$25.51 million

P/E RatioN/A

Dividend YieldN/A

Beta1.12

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for IRIDEX.

2.5 Community Rank

Outperform Votes
IRIDEX has received 183 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IRIDEX has received 180 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IRIDEX has received 50.41% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote “Outperform” if you believe IRIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IRIDEX does not currently pay a dividend.
Dividend Growth
IRIDEX does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IRIDEX insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of IRIDEX is held by insiders.
Percentage Held by Institutions
Only 32.87% of the stock of IRIDEX is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for IRIDEX are expected to decrease by -38.78% in the coming year, from ($0.49) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IRIDEX is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IRIDEX is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IRIDEX has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryN/A

SectorComputer and Technology

Current SymbolNASDAQ:IRIX

Previous Symbol

CUSIPN/A

CIK1006045

Webhttp://www.iridex.com/

Phone650-940-4700

Debt

Debt-to-Equity Ratio0.08

Current Ratio3.12

Quick Ratio2.29

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$43.45 million

Price / Sales0.59

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.65 per share

Price / Book1.12

Profitability

EPS (Most Recent Fiscal Year)($0.64)

Net Income$-8,810,000.00

Net Margins-20.28%

Return on Equity-35.33%

Return on Assets-23.51%

Miscellaneous

EmployeesN/A

Outstanding Shares13,787,000

Market Cap$25.51 million

Next Earnings Date5/7/2020 (Estimated)

OptionableNot Optionable

Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.

IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

How has IRIDEX's stock been impacted by COVID-19 (Coronavirus)?

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IRIX stock has decreased by 6.1% and is now trading at $1.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IRIDEX?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IRIDEX.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for IRIDEX.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) posted its earnings results on Thursday, March, 12th. The medical equipment provider reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The medical equipment provider earned $11.76 million during the quarter, compared to the consensus estimate of $11.70 million. IRIDEX had a negative net margin of 20.28% and a negative return on equity of 35.33%. View IRIDEX's earnings history.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX issued an update on its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $11.6-11.8 million, compared to the consensus revenue estimate of $10.88 million.

Has IRIDEX been receiving favorable news coverage?

Media headlines about IRIX stock have been trending very negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IRIDEX earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutIRIDEX.

Are investors shorting IRIDEX?

IRIDEX saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 6,400 shares, a decrease of 73.4% from the February 27th total of 24,100 shares. Based on an average trading volume of 25,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the stock are sold short. View IRIDEX's Current Options Chain.

Who are some of IRIDEX's key competitors?

Some companies that are related to IRIDEX include Fonar (FONR), Edap Tms (EDAP), Fc Global Realty (FCRE), electroCore (ECOR), Precision Optics (PEYE), Second Sight Medical Products (EYES), CHF Solutions (CHFS), ENDRA Life Sciences (NDRA), Viveve Medical (VIVE), Helius Medical Technologies (HSDT), Digirad (DRAD), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), ReShape Lifesciences (RSLSD) and Reshape Lifesciences (RSLS).

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include SCYNEXIS (SCYX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), CTI BioPharma (CTIC), Gilead Sciences (GILD), Trevena (TRVN), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Capstone Turbine (CPST) and Fate Therapeutics (FATE).

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:

Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
Mr. Romeo R. Dizon, VP of Fin.
Ms. Leigh Salvo, Head of Investor Relations
Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $1.85.

How big of a company is IRIDEX?

IRIDEX has a market capitalization of $25.51 million and generates $43.45 million in revenue each year. The medical equipment provider earns $-8,810,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. View additional information about IRIDEX.

What is IRIDEX's official website?

The official website for IRIDEX is http://www.iridex.com/.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff